Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
Ariceta G, Collard L, Abroug S, Moochhala SH, Gould E, Boussetta A, Ben Hmida M, De S, Hunley TE, Jarraya F, Fraga G, Banos A, Lindner E, Dehmel B, Schalk G. Ariceta G, et al. Among authors: dehmel b. Pediatr Nephrol. 2023 Feb;38(2):403-415. doi: 10.1007/s00467-022-05591-5. Epub 2022 May 12. Pediatr Nephrol. 2023. PMID: 35552824 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, Laskin B, Shahinfar S, Vande Walle J, Schaefer F. Warady BA, et al. Among authors: dehmel b. Pediatr Nephrol. 2019 Mar;34(3):475-486. doi: 10.1007/s00467-018-4116-y. Epub 2018 Nov 30. Pediatr Nephrol. 2019. PMID: 30506144 Clinical Trial.
An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. Sohn WY, et al. Among authors: dehmel b. Pediatr Nephrol. 2019 Jan;34(1):145-154. doi: 10.1007/s00467-018-4054-8. Epub 2018 Aug 23. Pediatr Nephrol. 2019. PMID: 30141180 Free PMC article. Clinical Trial.
Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. Sohn WY, et al. Among authors: dehmel b. Pediatr Nephrol. 2019 Apr;34(4):739-740. doi: 10.1007/s00467-018-4154-5. Pediatr Nephrol. 2019. PMID: 30536181 Free PMC article.
End Points for Clinical Trials in Primary Hyperoxaluria.
Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC. Milliner DS, et al. Among authors: dehmel b. Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1056-1065. doi: 10.2215/CJN.13821119. Epub 2020 Mar 12. Clin J Am Soc Nephrol. 2020. PMID: 32165440 Free PMC article.
40 results